CareDx to Present at UNOS Transplant Management Forum
04/16/2021 - 07:00 AM
Company to showcase its latest integrated solutions for improving care across the whole transplant journey
SOUTH SAN FRANCISCO, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will be exhibiting at the 29th Annual UNOS Transplant Management Forum (TMF), which takes place virtually between April 19-22, 2021.
On April 20, 2021 at 11:00 a.m. EDT, CareDx will be hosting a symposium titled “Providing Personalized Care for Every Step on the Transplant Journey,” which will include the following topics:
The Transplant Patient Pre-transplant Care with TX Connect and XynCare Quality Care with XynQAPI Post-transplant Care with AlloSure® dd-cfDNA “CareDx is thrilled to join TMF this year and share its comprehensive suite of integrated digital solutions that provide better tools for those who care for transplant patients,” said Kashif Rathore, Senior Vice President, Digital Business, CareDx. “With the recent inclusion of TX Connect into the CareDx family, we now offer solutions at every critical step of the transplant patient journey—from transplant referral to post transplant care.”
About CareDx www.CareDx.com .
CONTACTS:
Investor Relationsinvestor@caredx.com
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
